Global license provides American Regent, a wholly owned subsidiary of Daiichi Sankyo, with rights to commercialize Synoglide™ ...

Orthotics and exercise outperform medication: simple therapies offer greater relief for knee osteoarthritis with fewer risks.

Arthritis, a leading cause of disability, encompasses over 100 types, with osteoarthritis and rheumatoid arthritis being most ...

Eight-week study evaluates the “Leg Dexterity System,” a novel at-home device designed to improve mobility and reduce pain ...

Dr. Anderson said the treatment uses low doses of radiation to target inflamed joints. Dr. Anderson also said the ratiation reduces the activity of inflammatory cells and calms the body’s immune ...

Osteoarthritis, the most common cause of knee pain in adults over 50, affects more than 500 million people globally and is ...

Sue Harley, from Kings Heath, is enjoying time with her grandchildren - having initially not been sure she would even meet ...

Knee pain might seem like a natural part of aging, but new research shows it could be your body’s way of warning you about ...

Gallant is developing FDA-regulated, off-the-shelf mesenchymal stromal cell therapies to rapidly modulate inflammation, support tissue repair, and make stem cell treatment broadly available to cats ...

Detailed price information for Paradigm Biopharmaceuticals Ltd (PBIGF) from The Globe and Mail including charting and trades.

Home > Press release: Knee joint osteoarthritis replicated in ... Frankfurt UAS develops in vitro model for investigating early stages of the disease ...

Strong patient demand and expanding trial sites are helping Paradigm progress its long-awaited phase III knee OA study.